Detalle Publicación


Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Autores: Schalper, K. A. (Autor de correspondencia); Carleton, M. ; Zhou, M. ; Chen, T. ; Feng, Y. ; Huang, S. P.; Walsh, A. M.; Baxi, V.; Pandya, D.; Baradet, T. ; Locke, D. ; Wu, Q. Y.; Reilly, T. P.; Phillips, P. ; Nagineni, V.; Gianino, N.; Gu, J. L. ; Zhao, H. Y.; Pérez Gracia, José Luis; Fernández de Sanmamed Gutiérrez, Miguel; Melero Bermejo, Ignacio (Autor de correspondencia)
Título de la revista: NATURE MEDICINE
ISSN: 1078-8956
Volumen: 26
Número: 5
Páginas: 688 - 692
Fecha de publicación: 2020
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.